Literature DB >> 29588373

FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer.

Abdul Rehman1, Yeseul Kim1, Hyunsung Kim1, Jongmin Sim1, Hyein Ahn2, Min Sung Chung3, Su-Jin Shin1, Kiseok Jang1.   

Abstract

AIMS: Forkhead box O (FOXO) transcription factors, consisting of FOXO1, FOXO3a, FOXO4 and FOXO6, are involved in carcinogenesis and tumour progression. Recent studies have suggested that FOXOs act as tumour suppressors in a variety of human cancers. This study investigated the clinicopathological significance of FOXOs in triple-negative breast cancer (TNBC).
METHODS: FOXO protein expressions were assessed by immunohistochemistry in 125 TNBC tissues. Correlations between FOXO protein expression and various clinicopathological parameters, including patients' survival, were investigated. MDA-MB-468 cell line was used for in vitro cell proliferation and migration assay.
RESULTS: FOXO1 protein expression was not observed in all 125 TNBC tissues. FOXO4 and FOXO6 protein expressions were detected in 11 (8.8%) and 14 (11.2%) TNBC tissues, respectively. Loss of FOXO4 expression was significantly associated with high histological grade (P=0.014, χ2 test), and TNBCs with positive FOXO6 expression correlated with high grade (P=0.020, χ2 test). FOXO3a expression was detected in 40 (32%) TNBC cases and correlated with adverse clinicopathological features, such as lymph node metastasis (P=0.021, χ2 test), perineural invasion (P=0.013, χ2 test) and higher Ki-67 proliferation index (P=0.048, t-test). Additionally, FOXO3a expression was significantly associated with poor disease-free survival (P=0.015, log-rank test). In the in vitro study, siRNA-mediated FOXO3a knockdown in the MDA-MB-468 cell line inhibited cell proliferation and migration.
CONCLUSION: Among FOXO members, FOXO3a may have a potential role in promoting tumour cell migration and proliferation and may serve as a prognostic biomarker and a potential therapeutic target for TNBC. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  breast cancer; immunohistochemistry; metastasis

Mesh:

Substances:

Year:  2018        PMID: 29588373     DOI: 10.1136/jclinpath-2018-205052

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  11 in total

Review 1.  Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.

Authors:  Arijit Nath; Soham Mitra; Tanuma Mistry; Ranita Pal; Vilas D Nasare
Journal:  Med Oncol       Date:  2021-11-23       Impact factor: 3.064

2.  Retracted Article: FOXO4 overexpression suppresses hypoxia-induced-MCF-7 cell survival and promotes apoptosis through the HIF-2α/Bnip3 signal pathway.

Authors:  Yan Qiao; Bin Wang; Huimin Zhang; Yu Yan; Ligang Niu
Journal:  RSC Adv       Date:  2019-08-19       Impact factor: 4.036

3.  Adjudin synergizes with paclitaxel and inhibits cell growth and metastasis by regulating the sirtuin 3-Forkhead box O3a axis in human small-cell lung cancer.

Authors:  Xue Wang; Qingyu Zeng; Ziming Li; Xiao Yang; Weiliang Xia; Zhiwei Chen
Journal:  Thorac Cancer       Date:  2019-02-18       Impact factor: 3.500

4.  FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer.

Authors:  Michele Pellegrino; Pietro Rizza; Ada Donà; Alessandra Nigro; Elena Ricci; Marco Fiorillo; Ida Perrotta; Marilena Lanzino; Cinzia Giordano; Daniela Bonofiglio; Rosalinda Bruno; Federica Sotgia; Michael P Lisanti; Diego Sisci; Catia Morelli
Journal:  Cancers (Basel)       Date:  2019-11-25       Impact factor: 6.639

Review 5.  The role of FOXOs and autophagy in cancer and metastasis-Implications in therapeutic development.

Authors:  Mohd Farhan; Marta Silva; Shuai Li; Fengxia Yan; Jiankang Fang; Tangming Peng; Jim Hu; Ming-Sound Tsao; Peter Little; Wenhua Zheng
Journal:  Med Res Rev       Date:  2020-05-31       Impact factor: 12.944

6.  Inhibition of FOXO1‑mediated autophagy promotes paclitaxel‑induced apoptosis of MDA‑MB‑231 cells.

Authors:  Kaixiang Xu; Wanyun Zhu; Anyong Xu; Zhe Xiong; Di Zou; Heng Zhao; Deling Jiao; Yubo Qing; Muhammad Ameen Jamal; Hong-Jiang Wei; Hong-Ye Zhao
Journal:  Mol Med Rep       Date:  2022-01-11       Impact factor: 2.952

7.  FoxO3a Inhibits Tamoxifen-Resistant Breast Cancer Progression by Inducing Integrin α5 Expression.

Authors:  Elena Ricci; Mariarosa Fava; Pietro Rizza; Michele Pellegrino; Daniela Bonofiglio; Ivan Casaburi; Marilena Lanzino; Cinzia Giordano; Rosalinda Bruno; Rosa Sirianni; Ines Barone; Diego Sisci; Catia Morelli
Journal:  Cancers (Basel)       Date:  2022-01-02       Impact factor: 6.639

Review 8.  Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.

Authors:  Yixiao Feng; Mia Spezia; Shifeng Huang; Chengfu Yuan; Zongyue Zeng; Linghuan Zhang; Xiaojuan Ji; Wei Liu; Bo Huang; Wenping Luo; Bo Liu; Yan Lei; Scott Du; Akhila Vuppalapati; Hue H Luu; Rex C Haydon; Tong-Chuan He; Guosheng Ren
Journal:  Genes Dis       Date:  2018-05-12

Review 9.  Critical role of FOXO3a in carcinogenesis.

Authors:  Ying Liu; Xiang Ao; Wei Ding; Murugavel Ponnusamy; Wei Wu; Xiaodan Hao; Wanpeng Yu; Yifei Wang; Peifeng Li; Jianxun Wang
Journal:  Mol Cancer       Date:  2018-07-25       Impact factor: 27.401

10.  Repaglinide Silences the FOXO3/Lumican Axis and Represses the Associated Metastatic Potential of Neuronal Cancer Cells.

Authors:  Stefan Salcher; Gilles Spoden; Julia M Huber; Georg Golderer; Herbert Lindner; Michael J Ausserlechner; Ursula Kiechl-Kohlendorfer; Kathrin Geiger; Petra Obexer
Journal:  Cells       Date:  2019-12-18       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.